# STORM Therapeutics funding rounds and investors

As of 3 Nov 2026, STORM Therapeutics has raised $86M across 2 verified rounds on record, plus 3 rounds still being checked; latest: $56 million Series C, announced 16 Apr 2026.

STORM Therapeutics develops RNA modifying enzyme inhibitors for the treatment of sarcomas.

Website: https://stormtherapeutics.com  
Headquarters: Cambridge, United Kingdom  
Page: https://fireround.dev/companies/storm-therapeutics

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-04-16 | Series C | $56 million | not stated | Fast Track Initiative (FTI), M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo Innovation Platform | [stormtherapeutics.com](https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15), [globenewswire.com](https://www.globenewswire.com/news-release/2026/04/16/3275048/0/en/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15.html), [clinicaltrialvanguard.com](https://www.clinicaltrialvanguard.com/news/surging-storm-therapeutics-secures-56m-for-sarcoma-drug) |
| 2022-12-14 | Series B | USD $30 million | M Ventures, Pfizer Ventures, Taiho Ventures, Cambridge Innovation Capital, Fast Track Initiative (FTI), UTokyo Innovation Platform | IP Group, Seroba Life Sciences | [stormtherapeutics.com](https://www.stormtherapeutics.com/news/press-releases/storm-therapeutics-announces-closing-of-usd-30m-series-b-financing), [prnewswire.com](https://www.prnewswire.com/news-releases/storm-therapeutics-announces-closing-of-usd-30m-series-b-financing-301702426.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.